权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Using Cardiac Targeting Peptide to deliver miRNA for molecular reversal of heart failure

使用心脏靶向肽传递 miRNA 以分子逆转心力衰竭

基本信息

批准号：
10481720
负责人：
G IAN GALLICANO
金额：
$ 28.47万
依托单位：
VIVASC THERAPEUTICS INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-13 至 2024-07-12
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10481720
关键词：
Address Adult Affect Amino Acids Angiotensin II Angiotensin Receptor Angiotensin-Converting Enzyme Inhibitors Animal Model Apoptosis Arrhythmia Biodistribution Biological Assay Biotin CRISPR/Cas technology Cardiac Cardiac Myocytes Cell membrane Cell physiology Cells Cicatrix Complex Coupling Data Development Disease Dose Endothelial Cells Endothelium Environment Enzymes Epinephrine Event Exposure to Family Fibroblasts Gene Activation Gene Expression Genes Goals Health Heart Heart Hypertrophy Heart failure Human In Vitro Individual Inflammation Injections Intravenous Investigational Drugs Kidney Knock-out Knowledge Label Left Legal patent Letters Link Liver Logic Longevity Luciferases MicroRNAs Molecular Morbidity - disease rate Morphology Mus Myocardium Myofibroblast Nucleic Acids Nucleotides Organ Pathologic Pathway interactions Patients Pattern Peptides Persons Pharmaceutical Preparations Pharmacotherapy Phase Phase I Clinical Trials Phenotype Physiological Physiology Plant Roots Prevalence Process Protein Isoforms Publishing Quality of life Radioisotopes Recovery Relaxation Role Safety Signaling Molecule Small Business Technology Transfer Research Streptavidin Stress TXN gene Technology Testing Therapeutic Tissues Transcriptional Activation Treatment Failure Western Blotting Wild Type Mouse Work calmodulin-dependent protein kinase II cardiogenesis cell injury clinical development commercial application commercialization cost cyanine dye 5 disulfide bond improved in vivo in vivo evaluation in vivo imaging system induced pluripotent stem cell mortality mouse model novel overexpression pre-clinical side effect symptom treatment synthetic peptide targeted treatment technological innovation therapeutic miRNA therapeutically effective time use uptake vector

项目摘要

PROJECT SUMMARY/ABSTRACT Heart failure (HF) is a common disease with well-documented morbidity and mortality that affects approximately 23 million people globally, including 6 million in the US. Current HF medications such as Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs) treat the symptoms of HF versus the root cause of the disease, which includes stressed myocardium that leads to hypertrophic cardiomyocytes and endothelial inflammation. CaMKIIδ is a signaling molecule that regulates cellular pathways involved in excitation‑contraction coupling and relaxation events in the heart and transcriptional activation of genes related to cardiac hypertrophy, inflammation, and arrhythmias. If left uncorrected, CaMKIIδ‑regulated changes culminate in a dysfunctional myocardium and HF. The goal of this STTR Phase I project is to address this root cause of HF by delivering miRNA to cardiomyocytes to down-regulate the over-expression and/or activation of CaMKIIδ because this may allow damaged cardiomyocytes to regain normal function. To achieve this goal, a specific miRNA will be selected that effectively inhibits the expression of CaMKIIδ in vivo. This miRNA will then be conjugated to the proprietary cell penetrating peptide, Cardiac Targeting Peptide (CTP), developed by Vivasc Therapeutics. This will create a CTP-miRNA conjugate that will deliver this nucleotide specifically and directly to cardiomyocytes. CTP is a novel, synthetic peptide that has transduced (i) normal mouse hearts in vivo (peak uptake at 15 minutes after injection), (ii) explanted human heart tissue, and (iii) human derived iPSC beating cardiomyocytes. CTP has demonstrated robust transduction of normal cardiomyocytes while sparing myofibroblasts, endothelial cells, and fibroblasts present in scar tissue. To date, CTP conjugates have transduced cardiomyocytes carrying intact cargoes as diverse as radioisotopes, nucleic acids, other peptides, and conjugates as large as the biotin-streptavidin complex. The team’s preliminary data has shown that CTP is fully capable of carrying miRNA in a similar manner. The hypothesis is that CTP-miRNA will deliver miRNA to cardiomyocytes that are over expressing CaMKIIδ, thereby allowing damaged cardiomyocytes to regain normal function. The aims are: 1) deliver specific miRNAs to the hearts of HF mouse models to demonstrate their efficacy in reversing HF physiology and 2) test the in vivo biodistribution of CTP-miRNA using a dual-labeled CTP-miRNA. Phase II plans include conducting studies of optimized CTP-miRNA in larger animal models of HF and IND- enabling studies to support an Investigational New Drug (IND) submission for approval of a Phase 1 clinical trial. Upon approval, this treatment could potentially be prescribed to HF patients with cardiac hypertrophy, inflammation, and arrhythmias.

项目总结/文摘